Stuttgart
21.02.25
10:32 Uhr
0,315 Euro
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.02. | Alzinova AB: All study participants have completed the final visit in the Phase 1 study | 74 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) announces that another milestone in the development of the company's vaccine candidate ALZ-101 for Alzheimer's disease has been reached. All study participants have... ► Artikel lesen | |
| 28.01. | Alzinova AB: Alzinova strategically realigns CMO position to enhance collaboration and drive next development phase | 202 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) hereby announces that the Company's CMO is stepping down from her role after mutual agreement. The basis is a strategic decision to appoint a CMO in place at the Company's... ► Artikel lesen | |
| 09.12.24 | Alzinova AB: Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease | 133 | GlobeNewswire (Europe) | ALZ-101 continues to demonstrate a favorable safety and tolerability profile after at least 84 weeks of study inclusion.The immune response from vaccination with ALZ-101 is robust and long-lasting in... ► Artikel lesen | |
| 14.11.24 | Alzinova AB: Alzinova publishes interim report January - September 2024 | 112 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which... ► Artikel lesen | |
| 10.10.24 | Alzinova's new CEO to "The next six months will be really exciting" | 3 | Cision News | ||
| 22.08.24 | Alzinova AB: Alzinova publishes interim report January - June 2024 | 77 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period April - June, and the first half year, 2024. The full interim report, which is... ► Artikel lesen | |
| 04.06.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Alzinova AB (Record Id 265136) | 476 | GlobeNewswire | With effect from June 05, 2024, the subscription rights in Alzinova AB will be
traded on First North Growth Market. Trading will continue up until and
including June 17, 2024.
Instrument: Subscription... ► Artikel lesen | |
| ALZINOVA Aktie jetzt für 0€ handeln | |||||
| 30.05.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 30.05.2024 | 1.572 | Xetra Newsboard | Das Instrument IWY1 US82655M1071 SIFY TECHNO.LTD.ADR IR 10 EQUITY wird cum Kapitalmassnahme gehandelt am 30.05.2024 und ex Kapitalmassnahme am 31.05.2024 The instrument IWY1 US82655M1071 SIFY TECHNO.LTD.ADR... ► Artikel lesen | |
| 29.05.24 | Alzinova AB: Bulletin from the annual general meeting of Alzinova AB (publ) | 181 | GlobeNewswire (Europe) | Alzinova AB (publ) (the "Company") held its Annual General Meeting on 29 May 2024 in Gothenburg. Below is a summary of the resolutions that were passed. All resolutions were passed with the required... ► Artikel lesen | |
| 28.05.24 | Alzinova AB: Alzinova publishes interim report January - March 2024 | 324 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2024. The full interim report, which is attached in the press release... ► Artikel lesen | |
| 25.04.24 | Alzinova AB: Kristina Torfgård leaves the CEO position at Alzinova AB in July 2024 | 196 | GlobeNewswire (Europe) | Alzinova's CEO Kristina Torfgård has informed the Board of Directors that she wishes to step down as CEO of the company. Kristina will continue to focus on completing the phase 1b clinical study and... ► Artikel lesen | |
| 28.02.24 | Alzinova AB: Alzinova publishes Year-end report 2023 | 108 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year-end report for the period January - December 2023.
Three months, October - December 2023Net sales amounted... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,375 | -0,33 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch... ► Artikel lesen | |
| TEMPUS AI | 68,13 | -11,20 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 34,560 | -0,95 % | Harmony Biosciences price target cut to $42 at Mizuho | ||
| ARVINAS | 17,770 | -3,27 % | Arvinas Inc.: Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | - Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 - - Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,010 | 0,00 % | Dyne Therapeutics SVP Richard Scalzo verkauft Aktien im Wert von 34.707 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 9,265 | -10,48 % | Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX) | ||
| SPRINGWORKS THERAPEUTICS | 58,24 | -2,77 % | Merck KGaA: Wechsel im Top-Management - wann schlägt der DAX-Konzern bei SpringWorks zu? | Die Aktie von Merck KGaA notiert weiterhin in der Nähe des 52-Wochen-Tiefs. Das bestätigte Übernahmeinteresse an SprinWorks Therapeutics hat den DAX-Wert jüngst unter Druck gesetzt, denn die Marktteilnehmer... ► Artikel lesen | |
| EVOTEC | 8,520 | -0,35 % | Hebel-Idee | Turnaround-Chance: Nicht Bayer oder Evotec: Das könnte 2025 die beste Turnaround-Wette sein! | © Foto: picture alliance/Zoonar/Cigdem SimsekDie Anteile von SGL Carbon hatten in den vergangenen Jahren stark zu kämpfen, auch die letzten Monate waren von Verlusten geprägt. Jetzt könnte eine Gegenbewegung... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 36,810 | -1,58 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and... ► Artikel lesen | |
| BIONTECH | 114,20 | +0,44 % | Vervielfachungspotenzial mit KI-Newcomer NetraMark! Palantir und BioNTech in einer Aktie! | "Gamechanger"! "Quantensprung"! "Revolution"! Für die Möglichkeiten von Künstlicher Intelligenz (KI) in der Medizin verwenden Experten zahlreiche Superlative. Fest steht, dass KI riesiges Potenzial... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,430 | +1,76 % | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen | |
| DISC MEDICINE | 54,53 | +0,33 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| ABSCI | 4,960 | -4,43 % | Absci Corporation: Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery | VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,440 | -8,15 % | Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies | ||
| SUMMIT THERAPEUTICS | 22,090 | -4,21 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen |
ALZINOVA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,315 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZINOVA AB finden Sie auf Wallstreet Online.
